Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics has named Kirk Peacock to serve as its interim president. Mr Peacock, who has served on a part-time basis as ImmunoCellular’s chief financial officer since January 2006, will now serve as interim president on a part-time basis.
Subscribe to our email newsletter
ImmunoCellular (IMUC) has also announced that it has filed with the US patent office the two principal applications covering its multiple antigen dendritic cell cancer vaccine and cancer stem cell vaccine technologies that were the subject of provisional patent applications previously filed with the US patent office.
IMUC is currently funding a Phase I trial of the first technology, and is evaluating certain pre-clinical data for its cancer stem-cell vaccine technology to assess the feasibility of initiating a clinical development program for this technology in the treatment of brain tumors.
John Yu, chairman of the board, IMUC, said: “We are pleased that Kirk Peacock has agreed to serve on an interim basis as our president. We have launched an aggressive search to hire a full-time CEO with expertise and a proven track record of success in managing an early-stage biopharmaceutical company like ours.”